Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. - Wikidata - awgldk - TriplyDB

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q33591867

about

Acute lymphoblastic leukaemia Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications Diagnosis and subclassification of acute lymphoblastic leukemia Genomic profiling of B-progenitor acute lymphoblastic leukemia Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine Structural reorganization of the interleukin-7 signaling complex Structural basis of the proinflammatory signaling complex mediated by TSLP LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling.Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.Childhood B-acute lymphoblastic leukemia: a genetic update.Activation of JAK2-V617F by components of heterodimeric cytokine receptors Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.IL-7 in human health and disease.Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL.Next-generation cDNA screening for oncogene and resistance phenotypes.Rapid Identification of Therapeutic Targets in Hematologic Malignancies via Functional Genomics.Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia Mutations in G protein β subunits promote transformation and kinase inhibitor resistance Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target.Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

P2860

e21cf99a3ae6b0b3b0adebe8a9d5b2b56708a90a

P248

Q24602387-4142939B-0EA6-4ED4-A825-D4522021B972 Q26765647-AAEF38E1-B11F-4714-9758-369F45E1DFF1 Q26782539-24C45037-3459-4C69-AAC2-C489299B6768 Q26824387-63271F76-553B-44B2-A608-E3AEBD7EC740 Q26829976-1C8F6414-E6A7-46EB-B97C-38B34546E09E Q26864460-3137259A-C3D5-4397-BA25-43ED678CDF81 Q27677110-D377CB5B-25C0-43C0-A1EF-15670102A179 Q27689496-7FEF2CB3-FED4-40F8-9BFF-F133688B85FB Q28274115-AAC68FF4-5A5E-4452-BD61-4304F66B8222 Q28390558-4E2D1B96-896C-4A45-B746-4ACA8E1ACC9F Q30486787-A370E28E-1264-4BDB-BA31-54D319E2FB35 Q33691942-2A0D532A-5867-4BA2-A81D-A1FD3DDD5358 Q33698398-0FCF6AC4-2DB4-40E7-8BBA-3E6F12150E90 Q33777616-96DBFD3C-A31D-471F-A5CD-D6335AD75098 Q33883366-B8CCCF4E-27E6-4CA4-9505-F7F8180C2A4D Q33938184-0E16EE18-8550-4682-BED6-13B397795747 Q34021753-ACA1D755-2481-4E48-87CC-8E8F5EC098C0 Q34033206-522D0DB5-1CF3-4EF1-89DA-4712C8811F8F Q34162151-EF1EC62E-1383-4E0A-8E4B-4F904206C99E Q34168482-41755177-EF16-4AC3-96FB-0DBCE6DDEA97 Q34182738-5FB8B079-3361-4A84-A1BF-67EAF8A9712C Q34213539-0D4BC459-C2BB-495E-94C4-36466A1D0DBD Q34260682-5B28C68D-9424-41FE-97D5-CC2CBE77A2D4 Q34325528-F1062FF7-A04B-49FE-AE13-64B828C69AA1 Q34474239-9D670C97-0ED0-4CC7-88FE-6244AF346D57 Q34654334-8C36863A-714D-41F5-A34F-68D794A4B5F1 Q34755687-1C2BA9E6-EE09-4F06-9EB4-68292B1E69A1 Q34893087-30B6BBF6-FB73-4C81-BEFC-D20BA267AC96 Q34973772-D39B6C7B-B0A0-49F5-99F3-8A300F4D7F2F Q35002007-98C569B6-6911-4355-B815-135218C7AF23 Q35005652-0D0C5303-5DE9-4906-BE1D-339232A335EA Q35132241-C9BD3E0E-D20F-4BF4-A3A7-8AF1C22BFFFF Q35134457-1B505CF2-6683-4A96-B56C-CBBD6A169C56 Q35500533-E47AB3FA-3668-4985-9EA5-9D9E26BE66D6 Q35572318-819A3AD3-06EA-4685-8DB5-91596279931A Q35760845-7343586B-F24A-4447-8A1F-6F4066777ADE Q35861111-C54F0AEB-7C73-4BD4-9887-F27B4BF8F3C3 Q35876592-F07BB898-6ED2-4080-A6FB-57382F17BB4E Q35885293-8042A80A-6CE3-4D9A-A1AE-16EFC21C5390 Q35904943-49D98EA1-8782-4C1F-8E23-9FF5D8CFD904

P2860

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q33591867

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

@ast

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

@en

type

label

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

@ast

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

@en

prefLabel

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

@ast

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

@en

P1433

Q33591867-61B9F7D1-8A27-46B4-ABF0-98C30453751A

P1476

Q33591867-396A460A-0C4F-4CD0-B758-320ADFD1D49C

P2093

Q33591867-0EF62857-2773-4717-A7F6-D2E955B24556

Q33591867-1C95B261-1DC2-4004-B9D9-29803AF9FE1C

Q33591867-2555FBEB-5E71-42DF-A0F1-1533C74E58F5

Q33591867-36AFDEAB-E429-439F-A228-18D4644F32E3

Q33591867-443B018D-5E29-46E7-99D4-9B13A825AB49

Q33591867-50668CCB-CF08-4825-84FE-33FF43284F7F

Q33591867-56DE6B9B-9F04-4624-8293-E89D269C5FED

Q33591867-59ACDAA1-928F-4A6E-BF61-FCEE255D2E2C

Q33591867-5B75D585-8933-4098-84E7-D4DD66C3FE2A

Q33591867-5F6DC658-2F8C-4D2B-A53F-3D94D1C6C2D6

P2860

Q33591867-029A55FF-8F6D-4B24-9CC7-EE760AF6D919

Q33591867-06B7E279-7894-4FF0-A9AB-9C84F8AC4A13

Q33591867-109A7FDC-F90E-4421-8D55-6117F9076E9D

Q33591867-190F6CE4-8930-47AF-98CB-5993039B2736

Q33591867-2497C660-FF9C-4A2C-B79E-2F3C76A7AEB9

Q33591867-3835B2B9-8691-422F-A839-D7F90FFF58B4

Q33591867-3AF70016-681E-4609-A1FD-394D7C348634

Q33591867-3E331362-EE23-4C7B-B60E-BBA6146FE28B

Q33591867-435054BF-BCE5-4431-AA59-34318A92F4EA

Q33591867-439984CA-F7F6-4A6A-92FD-6226A1ED999C

P304

Q33591867-900E4194-8786-4231-8B6B-7495ED1ABD61

P31

Q33591867-6CF8A34B-3A45-43E5-8A3E-BF4221204BB5

P356

Q33591867-59A98A9C-AA26-4019-85DE-672FB23B97D0

P407

Q33591867-E01E68AB-4E30-4C41-B473-5B1F00003FD5

P433

Q33591867-0C4ED5D2-015B-4566-9CB6-BE020A4CF8BD

P478

Q33591867-BB7236DB-AD4B-4B1D-9D1F-6480BC86DAFA

P50

Q33591867-43C410E7-2C42-453A-B6A4-1C3BA48CBE20

Q33591867-A5FE49B5-0DCF-4AFD-8152-9BA3398F4B87

Q33591867-F83E7873-2828-44AF-981F-9025CA884CCC

P577

Q33591867-1D4A856E-846E-4527-9CCA-7F2213CFB8D6

P5875

Q33591867-1DC35B88-B1C0-4DD6-BDDB-FDEACAF9EAC6

P698

Q33591867-370E0796-56B6-45B6-9CA9-7FC06404D7FC

P921

Q33591867-017EED6C-D2B6-42C6-9AF6-A7BD926E80BC

P932

Q33591867-2A398CE4-3043-4191-BE6C-130931CC24DA

P356

PNAS.0911726107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

@en

P2093

Akinori Yoda

http://www.w3.org/2001/XMLSchema#string

Alfonso Piciocchi

http://www.w3.org/2001/XMLSchema#string

Constantine Mitsiades

http://www.w3.org/2001/XMLSchema#string

Daniel J DeAngelo

http://www.w3.org/2001/XMLSchema#string

David A Frank

http://www.w3.org/2001/XMLSchema#string

David M Weinstock

http://www.w3.org/2001/XMLSchema#string

James D Griffin

http://www.w3.org/2001/XMLSchema#string

James E Bradner

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Kutok

http://www.w3.org/2001/XMLSchema#string

Jennifer R Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP, a sentinel for epidermal integrity

Activating mutations in ALK provide a therapeutic target in neuroblastoma.

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains.

STAT signaling in the pathogenesis and treatment of leukemias.

Human thymic stromal lymphopoietin preferentially stimulates myeloid cells.

Mechanisms promoting translocations in editing and switching peripheral B cells.

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.

Mechanisms of chromosomal translocations in B cell lymphomas.

P304

252-257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0911726107

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Martha Wadleigh

P577

2009-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40696124

http://www.w3.org/2001/XMLSchema#string

P698

20018760

http://www.w3.org/2001/XMLSchema#string

P921

P932

2806782

http://www.w3.org/2001/XMLSchema#string